Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
